Myriad prenatal sale terms announced on October 20, 2026, call for Labcorp to buy Myriad Genetics’ Prenatal Health testing business for $210 million in cash, plus the value of inventory at closing. The definitive agreement would shift the testing portfolio to Labcorp while supporting Myriad’s planned focus on cancer care. Completion is expected by early 2027, subject to regulatory clearance and customary closing conditions.
Key Takeaways
- The $210 million cash price excludes inventory value, which will be added at closing.
- Labcorp forecasts approximately $160 million in revenue from the business in its first year.
- Myriad plans further transaction commentary on its November 4, 2026, earnings call.
Table of Contents
- Myriad prenatal sale covers four testing products
- The companies pursue different strategic benefits
- Regulatory clearance remains a condition of completion
- Conclusion
Myriad prenatal sale covers four testing products
Myriad’s definitive sale announcement identifies Prequel, Foresight, SneakPeek and FirstGene as the tests included in the transaction. The agreement is signed, but ownership has not yet transferred.
Over the preceding 12 months, the prenatal testing portfolio was used by thousands of providers and more than 600,000 patients. The companies expect the combination to expand access through Labcorp’s laboratory services, patient service centers and digital tools.
Myriad Chief Executive Officer Sam Raha said the companies expect a smooth transition that preserves uninterrupted patient access. That remains a transition objective rather than a completed outcome.
| Item | Details |
|---|---|
| Labcorp first-year revenue outlook | Approximately $160 million from the acquired business. |
| Labcorp first-year adjusted earnings outlook | Expected to be slightly accretive. |
| Labcorp integration margin target | Average diagnostics segment margins by the end of year two, once fully integrated. |
The companies pursue different strategic benefits
Raha described the divestiture as an outcome of Myriad’s strategic review. Management expects it to strengthen the balance sheet, improve the remaining business’s revenue growth and profitability, and support investment in priorities across the cancer care continuum.
For Labcorp, the acquisition would expand its specialty testing business and women’s health portfolio. Bryan Vaughn, executive vice president and president of Diagnostics, said combining Myriad’s reproductive genetics capabilities with Labcorp’s operations is intended to improve access and the patient and provider experience.
Labcorp’s financial targets distinguish the initial contribution from the benefits expected after integration. Its earnings and margin expectations are forward-looking, not results already achieved.
Regulatory clearance remains a condition of completion
The early-2027 closing target depends on regulatory clearance and other customary requirements. The announced cash consideration is also not the final total payment, because inventory will be valued at closing.
Myriad plans to discuss the transaction and related organizational changes on its third-quarter earnings call on November 4, 2026. The announcement did not detail those organizational changes.
Conclusion
The agreement would give Myriad cash to support its cancer-care priorities and add a reproductive genetics portfolio to Labcorp. The next scheduled update is Myriad’s November 4 earnings call, ahead of the targeted early-2027 closing.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
